FIG 1.

Baseline mutational profile. Pretreatment circulating tumor DNA analysis showing nonsynonymous variants (green), indels (golden brown), or both (red) detected in each gene for the 62 patients with at least one baseline mutation identified. Each row indicates a gene for which one or more patient had a mutation detected, with rows ordered from top to bottom based on decreasing prevalence of mutations. Number of variants detected in each patient is represented by the height of the bars and patients are arranged in increasing order. The four rows at the bottom indicate assessment of response at 6 months with DCB (green), NDB (beige), and one patient without a 6-month assessment (dark gray); treatment with pembrolizumab monotherapy (gold) or pembrolizumab plus chemotherapy (light purple); PD-L1 status with PD-L1 > 50% (blue); and smoking status with current (dark purple), former (teal), and never smokers (light gray). DCB, durable clinical benefit; NDR, no durable benefit; PD-L1, programmed death ligand 1; SNV, single nucleotide variant.